Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.

Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.

A nonmyeloablative conditioning regimen was investigated in 47 patients with hematological malignancy receiving allogeneic progenitor cells from matched, unrelated donors. The median patient age was 44 years. The majority of patients had high-risk features, including having failed a prior transplant...

Full description

Bibliographic Details
Main Authors:	Chakraverty, R, Peggs, K, Chopra, R, Milligan, D, Kottaridis, P, Verfuerth, S, Geary, J, Thuraisundaram, D, Branson, K, Chakrabarti, S, Mahendra, P, Craddock, C, Parker, A, Hunter, A, Hale, G, Waldmann, H, Williams, C, Yong, K, Linch, D, Goldstone, A, Mackinnon, S
Format:	Journal article
Language:	English
Published:	2002

Similar Items

In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.
by: Kottaridis, P, et al.
Published: (2000)

In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.
by: Kottaridis, P, et al.
Published: (2001)

High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution.
by: Chakrabarti, S, et al.
Published: (2002)

Excessive T-cell depletion adversely affects transplant-related mortality following allogeneic stem cell transplantation.
by: Chakraverty, R, et al.
Published: (2000)

Excessive T cell depletion of peripheral blood stem cells has an adverse effect upon outcome following allogeneic stem cell transplantation.
by: Chakraverty, R, et al.
Published: (2001)

HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning.
by: Mead, A, et al.
Published: (2010)

Preliminary results of an non-myeloablative conditioning regimen for allogeneic stem cell transplantation.
by: Mackinnon, S, et al.
Published: (1999)

T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor lymphocyte infusions.
by: D'Sa, S, et al.
Published: (2003)

Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation.
by: Chakrabarti, S, et al.
Published: (2003)

Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation.
by: Peggs, K, et al.
Published: (2005)

Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.
by: Peggs, K, et al.
Published: (2003)

Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality.
by: Chakrabarti, S, et al.
Published: (2002)

Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab.
by: Avivi, I, et al.
Published: (2004)

An unusual case of intrapulmonary granulocytic sarcoma presenting as interstitial pneumonitis following allogeneic bone marrow transplantation for acute myeloid leukaemia and responding to donor lymphocyte infusion.
by: Kottaridis, P, et al.
Published: (1999)

A non myeloablative regimen for allografting high-risk patients: Low toxicity, stable engraftment without GVHD, disease control and potential for GVL with adoptive immunotherapy.
by: Kottaridis, P, et al.
Published: (1999)

Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide
by: Ashley Munchel, et al.
Published: (2011-06-01)

Trasplante no mieloablativo de células hematopoyéticas Nonmyeloablative transplantation of haematopoietic cells
by: Valia Pavón Morán, et al.
Published: (2003-12-01)

Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
by: Hale, G, et al.
Published: (2002)

Donor lymphocyte infusion in bone marrow transplantation therapy
by: Stephen Mackinnon, et al.
Published: (2002-04-01)

BONE-MARROW TRANSPLANTATION (BMT) FOR CHRONIC MYELOID-LEUKEMIA (CML) USING MATCHED UNRELATED DONORS
by: Mackinnon, S, et al.
Published: (1988)

BONE-MARROW TRANSPLANTATION (BMT) FOR CHRONIC MYELOID-LEUKEMIA (CML) USING MATCHED UNRELATED DONORS
by: Mackinnon, S, et al.
Published: (1988)

BONE-MARROW TRANSPLANTATION USING UNRELATED DONORS FOR CML IN CHRONIC PHASE
by: Cullis, J, et al.
Published: (1991)

Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.
by: Chakraverty, R, et al.
Published: (2010)

Unrelated donor bone marrow transplant in childhood ALL. The role of T-cell depletion.
by: Cornish, J, et al.
Published: (1996)

Matched unrelated donor bone marrow transplantation for chronic myeloid leukaemia in chronic phase: comparison of ex vivo and in vivo T-cell depletion.
by: Cullis, J, et al.
Published: (1993)

Unrelated Donor Bone Marrow Transplants in Children
by: Alfred Grovas, et al.
Published: (1994-09-01)

Bone marrow transplantation for chronic myeloid leukemia: the use of histocompatible unrelated volunteer donors.
by: Mackinnon, S, et al.
Published: (1990)

CAMPATH-1 antibodies in stem-cell transplantation.
by: Hale, G, et al.
Published: (2001)

Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia.
by: Craddock, C, et al.
Published: (2010)

Kinetics of IL-7 and IL-15 levels after allogeneic peripheral blood stem cell transplantation following nonmyeloablative conditioning.
by: Muriel De Bock, et al.
Published: (2013-01-01)

Fludarabine and cyclophosphamide provides a nonmyeloablative alternative conditioning regimen with low transplant-related mortality and control of high risk disease
by: Pamela Paplham, et al.
Published: (2014-01-01)

Extension of Maximal Lifespan and High Bone Marrow Chimerism After Nonmyeloablative Syngeneic Transplantation of Bone Marrow From Young to Old Mice
by: Marina V. Kovina, et al.
Published: (2019-04-01)

MHC haplotype matching for unrelated hematopoietic cell transplantation.
by: Effie W Petersdorf, et al.
Published: (2007-01-01)

Microvascular Complications in Type 1 Diabetes: A Comparative Analysis of Patients Treated with Autologous Nonmyeloablative Hematopoietic Stem-Cell Transplantation and Conventional Medical Therapy
by: Jaquellyne G. Penaforte-Saboia, et al.
Published: (2017-11-01)

Unrelated donors in kidney transplantation: Myths and the gruesome reality
by: Taqi F Toufeeq Khan, et al.
Published: (2020-01-01)

(GT)n Repeat Polymorphism in Heme Oxygenase-1 (HO-1) Correlates with Clinical Outcome after Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation.
by: Tania Køllgaard, et al.
Published: (2016-01-01)

WHAT UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THALASSEMIA TAUGHT US ABOUT TRANSPLANT IMMUNOGENETICS.
by: Giorgio La Nasa, et al.
Published: (2016-10-01)

Stem cell transplantation: preventing relapse of transplant
by: Charles Craddock
Published: (2018-06-01)

A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia
by: Simona Piemontese, et al.
Published: (2017-01-01)

Immunological aspects of unrelated bone marrow transplantation: alloreactivity and immunoreconstitution
by: Madrigal J. Alejandro
Published: (2001-01-01)